C-reactive protein and venous thromboembolism: A prospective investigation in the ARIC cohort

Thrombosis and Haemostasis

Volumn 102, Issue 4, 2009, Pages 615-619

  Folsom, Aaron R ^a   Lutsey, Pamela L ^a   Astor, Brad C ^b   Cushman, Mary ^c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

C reactive protein; Prospective study; Pulmonary embolus; Venous thrombosis

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HAZARD RATIO; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POPULATION GROUPS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 70449491315     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-04-0274     Document Type: Article

References (26)

1. Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264: 295-314.
2. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979. (Pubitemid 27152782)
3. Tsai AW, Cushman M, Rosamond WD, et al. Co-agulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002; 113: 636-642. (Pubitemid 36015799)
4. Mahmoodi BK, Gansevoort RT, Veeger NJGM, et al. Microalbuminuria and risk of venous thromboembolism. JAMA 2009; 301: 1790-1797.
5. Kamphuisen PW, Eikenboom JCJ, Vos HL, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-683.
6. Vormittag R, Vukovich T, Schönauer V, et al. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost 2005; 93: 488-493. (Pubitemid 40392537)
7. Zee RYL, Hegener HH, Cook NR, et al. C-reactive protein gene polymorphisms and the risk of venous thromboembolism: a haplotype-based analysis. J Thromb Haemost 2004; 2: 1240-1243. (Pubitemid 40186114)
8. Vormittag R, Funk M, Mannhalter C, et al. C-reactive protein 3' UTR + 1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis 2006; 188: 406-411. (Pubitemid 44301137)
9. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002; 116; 173-177. (Pubitemid 34122078)
10. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004; 2: 619-622.
11. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362-365.
12. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. Am J Epidemiol 1989; 129: 687-702.
13. Zakai NA, Ohira T, White R, et al. Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med 2008; 121: 231-238. (Pubitemid 351317918)
14. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: The Longitudinal Investigation of Thromboembolism Etiology. Am J Med 2004; 117: 19-25. (Pubitemid 38801482)
15. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-58. (Pubitemid 27024390)
16. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
17. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520. (Pubitemid 23206115)
18. Chooi CC, Gallus AS. Acute phase reaction, fibrinogen level and thrombus size. Thromb Res 1989; 53: 493-501.
19. Prandoni P, Bilori F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
20. Reich LM, Folsom AR, Key NS, et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006; 4: 1909-1913. (Pubitemid 44226767)
21. Sørensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-1779. (Pubitemid 350137491)
22. Lowe GDO. Is venous thrombosis a risk factor for arterial thrombosis? Lancet 2007; 370: 1742-1743.
23. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44: 62-69. (Pubitemid 46553809)
24. Ageno W, Becattini C, Brighton T, et al. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117: 93-102. (Pubitemid 350301144)
25. Fibrinogen Studies Collaboration (Danesh J, Lewington S, Thompson SG, et al). Plasma fibrinogen level and the risk of major cardiovascular diseases and non-vascular mortality: an individual participant metaanalysis. JAMA 2005; 294: 1799-1809.
26. Koster T, Rosendaal FR, Reitsma PH, et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-722. (Pubitemid 24177958)